Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GTBP NASDAQ:RDHL OTCMKTS:SKVI OTCMKTS:SRNEQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGTBPGT Biopharma$0.94+1.2%$1.80$0.88▼$4.10$3.30M1.36124,710 shs3.23 million shsRDHLRedhill Biopharma$1.43+16.5%$1.62$1.06▼$12.50$2.82M4.2589,434 shs125,018 shsSKVISkinvisible$0.23+9.5%$0.20$0.14▼$0.85$1.24M0.863,365 shs1,200 shsSRNEQSorrento Therapeutics$0.00+2.8%$0.00$0.00▼$0.42$2.04M2.25511,766 shs36,874 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGTBPGT Biopharma+1.18%+0.59%-45.98%-64.93%-56.88%RDHLRedhill Biopharma+16.54%+6.19%+16.54%-27.96%-83.56%SKVISkinvisible+9.48%+47.56%+0.92%+35.87%-65.15%SRNEQSorrento Therapeutics-28.00%-40.00%+56.52%+71.43%-40.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGTBPGT Biopharma$0.94+1.2%$1.80$0.88▼$4.10$3.30M1.36124,710 shs3.23 million shsRDHLRedhill Biopharma$1.43+16.5%$1.62$1.06▼$12.50$2.82M4.2589,434 shs125,018 shsSKVISkinvisible$0.23+9.5%$0.20$0.14▼$0.85$1.24M0.863,365 shs1,200 shsSRNEQSorrento Therapeutics$0.00+2.8%$0.00$0.00▼$0.42$2.04M2.25511,766 shs36,874 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGTBPGT Biopharma+1.18%+0.59%-45.98%-64.93%-56.88%RDHLRedhill Biopharma+16.54%+6.19%+16.54%-27.96%-83.56%SKVISkinvisible+9.48%+47.56%+0.92%+35.87%-65.15%SRNEQSorrento Therapeutics-28.00%-40.00%+56.52%+71.43%-40.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGTBPGT Biopharma 3.50Strong Buy$11.001,070.21% UpsideRDHLRedhill Biopharma 0.00N/AN/AN/ASKVISkinvisible 0.00N/AN/AN/ASRNEQSorrento Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGTBPGT BiopharmaN/AN/AN/AN/A($0.75) per shareN/ARDHLRedhill Biopharma$8.04M0.41N/AN/A($3.66) per share-0.39SKVISkinvisible$20K62.12N/AN/A($1.86) per share-0.12SRNEQSorrento Therapeutics$62.84M0.03N/AN/A($0.05) per share-0.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGTBPGT Biopharma-$13.16M-$4.07N/AN/AN/AN/A-1,804.34%-200.12%11/13/2025 (Estimated)RDHLRedhill Biopharma-$8.27MN/A0.00∞N/AN/AN/AN/AN/ASKVISkinvisible-$570K-$0.08N/A∞N/A-2,635.00%N/A-351.46%N/ASRNEQSorrento Therapeutics-$572.84MN/A0.00∞N/AN/AN/AN/AN/ALatest SKVI, GTBP, SRNEQ, and RDHL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025GTBPGT Biopharma-$0.68-$0.55+$0.13-$0.55N/AN/A8/13/2025Q2 2025SKVISkinvisibleN/A-$0.05N/A-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGTBPGT BiopharmaN/AN/AN/AN/AN/ARDHLRedhill BiopharmaN/AN/AN/AN/AN/ASKVISkinvisibleN/AN/AN/AN/AN/ASRNEQSorrento TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGTBPGT BiopharmaN/A2.762.76RDHLRedhill BiopharmaN/A0.540.37SKVISkinvisibleN/A0.010.01SRNEQSorrento TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGTBPGT Biopharma8.15%RDHLRedhill Biopharma7.20%SKVISkinvisibleN/ASRNEQSorrento Therapeutics0.02%Insider OwnershipCompanyInsider OwnershipGTBPGT Biopharma3.40%RDHLRedhill Biopharma6.81%SKVISkinvisible53.00%SRNEQSorrento Therapeutics2.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGTBPGT Biopharma83.56 million3.44 millionNo DataRDHLRedhill Biopharma2102.30 million2.14 millionNo DataSKVISkinvisible25.40 million2.54 millionNot OptionableSRNEQSorrento Therapeutics800551.28 million536.95 millionNot OptionableSKVI, GTBP, SRNEQ, and RDHL HeadlinesRecent News About These CompaniesSorrento Therapeutics Restructuring Chief Hosted Party for Judges Who Later Oversaw Its LiquidationSeptember 3, 2024 | wsj.comSorrento, Naples, Italy Weather Conditionsstar_ratehomeAugust 28, 2024 | wunderground.comWSorrento, British Columbia, Canada 10-Day Weather Forecaststar_ratehomeAugust 26, 2024 | wunderground.comWSorrento Announces New Board MemberAugust 22, 2024 | br.advfn.comSorrento wins DoJ’s venue-based challenge to bankruptcy filingMarch 12, 2024 | msn.comSorrento’s Bankruptcy Venue Action Is ‘Unprecedented,’ DOJ SaysMarch 9, 2024 | news.bloomberglaw.comNLatham, Jackson Walker avoid sanctions over bankruptcy forum shopping disputeFebruary 29, 2024 | reuters.comVirpax reaches deal to settle litigation with Sorrento Therapeutics, Scilex PharmaceuticalsFebruary 27, 2024 | bizjournals.comSorrento Therapeutics Stock (OTC:SRNEQ) Dividends: History, Yield and DatesFebruary 22, 2024 | benzinga.comSorrento faked venue in bankruptcy filing, Justice Department saysFebruary 21, 2024 | msn.comSorrento Therapeutics Inc (SRNEQ) Earnings Dates & ReportsNovember 18, 2023 | investing.comScilex Holding Company Retains Warshaw Burstein, LLP and Christian Attar Law to Investigate ...October 7, 2023 | bakersfield.comBScilex Holding Company Retains Warshaw Burstein, LLP and Christian Attar Law to Investigate Potential Naked Short Selling, Short Positions, Stock Lending Program Activities and Market Manipulation of Its Stock PriceOctober 7, 2023 | finance.yahoo.comScilex Holding Company Provides Notice to All Lenders of Short Positions in the Restricted ...October 4, 2023 | bakersfield.comBScilex Holding Company Provides Notice to All Record Holders and Beneficial Owners of Restricted Shares of Scilex Holding CompanyOctober 3, 2023 | finance.yahoo.comScilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.September 21, 2023 | finance.yahoo.comScilex Holding Company Announces the Completion of its SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, Phase 2 trial which achieved its objectives to Evaluate the Safety and Efficacy of SP-103 in Subjects with Moderate to Severe Acute Lower Back Pain (LBP)September 14, 2023 | finance.yahoo.comScilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful BidderSeptember 13, 2023 | finance.yahoo.comSorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19September 12, 2023 | finance.yahoo.comScilex Holding Company Generates Record Monthly Revenue In August 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended August 2023, And Year-To-Date As Of August 31 2023, Based On Currently Available InformationSeptember 11, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSKVI, GTBP, SRNEQ, and RDHL Company DescriptionsGT Biopharma NASDAQ:GTBP$0.94 +0.01 (+1.18%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$0.88 -0.05 (-5.85%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.Redhill Biopharma NASDAQ:RDHL$1.43 +0.20 (+16.54%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$1.45 +0.01 (+0.87%) As of 09/5/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.Skinvisible OTCMKTS:SKVI$0.23 +0.02 (+9.48%) As of 09/5/2025 10:37 AM EasternSkinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company's flagship product is Invisicare, a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. It also develops and licenses prescription and over-the-counter products to pharmaceutical and consumer goods companies; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada.Sorrento Therapeutics OTCMKTS:SRNEQ$0.0037 +0.00 (+2.78%) As of 09/5/2025Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
